News stories about Cumberland Pharmaceuticals (NASDAQ:CPIX) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cumberland Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 47.0819617436028 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Cumberland Pharmaceuticals (CPIX) opened at $7.11 on Friday. The firm has a market capitalization of $111.50, a PE ratio of -14.22 and a beta of 0.85. The company has a current ratio of 4.18, a quick ratio of 3.81 and a debt-to-equity ratio of 0.12. Cumberland Pharmaceuticals has a 12-month low of $5.28 and a 12-month high of $7.96.
Separately, ValuEngine lowered Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.